3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
2
Unknown
1
Completed
1
Approved for marketing
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Renal Insufficiency
2
Neurotoxicity Syndromes
2
Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neoplasms
1
Mucositis
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia
1
Interventions
Ifosfamide
17
Methotrexate
16
Doxorubicin
14
Filgrastim
13
Etoposide
12
Cisplatin
12
Cyclophosphamide
10
Gemcitabine
9
Leucovorin
8
Sirolimus
6
Carboplatin
6
Topotecan
5
Irinotecan
5
Granulocyte Colony-Stimulating Factor
5
Temozolomide
4
Sorafenib
4
Radiotherapy
4
Peripheral Blood Stem Cell Transplantation
4
Docetaxel
4
trimetrexate glucuronate
3
temsirolimus
3
dinutuximab
3
cixutumumab
3
apatinib
3
Vincristine
3
Specimen Handling
3
Oxaliplatin
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Osteosarcoma
×
glucarpidase
×
Clear all
NCT00634504
2022-06-06
LVPK
BTG International Inc.
Phase 1
Completed
20 enrolled
9 charts